Post by Medical Device Network

Boston Scientific has reported revenue of around $5.2bn in Q1 2026, broadly in line with performance achieved in Q4 2025, yet has tempered its full-year growth expectations. The medtech giant’s Q1 revenues correspond to a year-over-year (YoY) uptick of 11.2% on the quarter’s 2025 performance of around $4.7bn. For 2026, Boston now expects growth to fall in the range between 7% to 8.5% versus 10.5% to 11.5% as outlined previously, with earnings between $3.34 and $3.41 per share compared with a previously mooted range between $3.43 and $3.49. Elaborating on the decision to trim its full-year 2026 outlook, Boston CEO Mike Mahoney stated during a conference call that the company felt this was a “prudent move” that reflected “ongoing competitive dynamics” offset by strength in the company’s evolving Farapulse PFA catheter and mapping portfolio. #PFA #medtech #cardiovascular #medtechfinancials Read the full report below: https://lnkd.in/eqhY_k7Q